Enanta Pharmaceuticals Inc
NASDAQ:ENTA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Enanta Pharmaceuticals Inc
Short-Term Investments
Enanta Pharmaceuticals Inc
Short-Term Investments Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Short-Term Investments | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Enanta Pharmaceuticals Inc
NASDAQ:ENTA
|
Short-Term Investments
$148.4m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
1%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Short-Term Investments
$28m
|
CAGR 3-Years
0%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
13%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Short-Term Investments
$68m
|
CAGR 3-Years
-59%
|
CAGR 5-Years
-45%
|
CAGR 10-Years
-28%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Short-Term Investments
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Short-Term Investments
$1.5B
|
CAGR 3-Years
77%
|
CAGR 5-Years
18%
|
CAGR 10-Years
17%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Short-Term Investments
$5.5B
|
CAGR 3-Years
6%
|
CAGR 5-Years
32%
|
CAGR 10-Years
37%
|
|
Enanta Pharmaceuticals Inc
Glance View
Enanta Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. The company is headquartered in Watertown, Massachusetts and currently employs 155 full-time employees. The company went IPO on 2013-03-21. The firm is engaged in development of small molecule drugs for the treatment of viral infections and liver diseases. The firm has clinical candidates for the disease targets, including respiratory syncytial virus (RSV), hepatitis B virus (HBV) and non-alcoholic steatohepatitis (NASH). The firm has discovered glecaprevir, a protease inhibitor discovered and developed for the treatment of chronic hepatitis C virus (HCV). Glecaprevir is co-formulated direct-acting antiviral (DAA), a combination treatment for HCV infection under the tradenames: MAVYRET and MAVIRET. Its product candidates also include EDP-514, EDP-305 and EDP-938. The firm's subsidiary is Enanta Pharmaceuticals Security Corporation.
See Also
What is Enanta Pharmaceuticals Inc's Short-Term Investments?
Short-Term Investments
148.4m
USD
Based on the financial report for Dec 31, 2025, Enanta Pharmaceuticals Inc's Short-Term Investments amounts to 148.4m USD.
What is Enanta Pharmaceuticals Inc's Short-Term Investments growth rate?
Short-Term Investments CAGR 10Y
1%
Over the last year, the Short-Term Investments growth was 12%. The average annual Short-Term Investments growth rates for Enanta Pharmaceuticals Inc have been -5% over the past three years , -15% over the past five years , and 1% over the past ten years .
